Filtern Sie alle Angebote nach Fachbereich
Targeted therapy has become a promising therapeutic approach within the last decade due to its reduced toxicity. However, further development of targeted approaches for the specific delivery of therapeutically active substances is required. Especially the targeted delivery of macromolecular charged drug-like molecules, for example antagomirs and siRNA, is limited since these candidates do not cross cell membranes but rather have to be actively provided to the intracellular milieu.
The present invention provides novel aptamers capable of recognizing tumour cells and delivering macromolecular molecules into tumour cells. Aptamers are short single-stranded nucleic acids that recognize specific target structures with high affinity and specificity. Additionally, since aptamers have been shown to possess almost no toxicity and immunogenicity they are promising candidates for biomedical applications.
Surprisingly, the identified aptamers recognize various cancer cells particularly those derived from solid tumours, while non-tumourgenic and primary healthy cells are not recognized.
Thus, these findings render the aptamers applicable as broad-spectrum diagnostics and therapeutics.
The described technology enables diagnosis and treatment of several tumour types with one formulation, thereby reducing the developing costs for pharmaceuticals.
On behalf of the University Bonn, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development.
In case of interest we are pleased to inform you about the current patent Status.